We conducted a prospective , randomized , open-label , multicenter study to compare busulfan plus fludarabine ( BuFlu ) with busulfan plus cyclophosphamide ( BuCy ) as the conditioning regimen in allogeneic hematopoietic stem cell transplantation ( allo-HSCT ) for acute myeloid leukemia ( AML ) in first complete remission ( CR1 ) .
